IGC Pharma
23 hedge funds and large institutions have $900K invested in IGC Pharma in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 5 closing their positions.
430% more call options, than puts
Call options by funds: $53K | Put options by funds: $10K
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
0.46% less ownership
Funds ownership: 5.55% → 5.1% (-0.46%)
4% less capital invested
Capital invested by funds: $937K → $900K (-$37.6K)
12% less funds holding
Funds holding: 26 → 23 (-3)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Group One Trading
Chicago,
Illinois
|
+$4.28K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$4.01K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$3.97K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$3.01K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$8 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$41.9K |
| 2 |
VF
Virtu Financial
New York
|
-$21K |
| 3 |
Millennium Management
New York
|
-$15.4K |
| 4 |
Jane Street
New York
|
-$8.51K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$7.15K |
IGC Hedge Fund Activity: Q1 2023 in Review
23 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in IGC Pharma (IGC) for Q1 2023, worth a combined $900K — down 4% from $937K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of IGC and 2 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 6 added.
The largest buyer was Group One Trading, adding an estimated $4.28K. The largest seller was Renaissance Technologies, cutting an estimated $41.9K.
- 23 institutional investors held IGC Pharma (IGC) as of Q1 2023, down from 26 in Q4 2022.
- Funds reported $900K of IGC Pharma stock for Q1 2023, down 4% quarter-over-quarter.
- 2 funds opened new IGC Pharma positions in Q1 2023 and 5 closed out, a net change of -3 holders.
- The largest IGC Pharma buyer in Q1 2023 was Group One Trading, an estimated $4.28K added.
- The largest IGC Pharma seller in Q1 2023 was Renaissance Technologies, an estimated $41.9K sold.
Based on aggregated 13F filings for Q1 2023.